I. B. Esmagambetov

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet · 2021 · 1.8K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov, Inna V. Dolzhikova, Olga V. Zubkova et al. · The Lancet · 2020 · 1.1K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice

Svetlana A. Godakova, A. N. Noskov, I. D. Vinogradova et al. · Toxins · 2019 · 75 citations · Full text

Life Sciences, Biomolecular Engineering, Immunology +17

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults

Amir I. Tukhvatulin, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet Regional Health - Europe · 2021 · 71 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern

I. A. FAVORSKAYA, Dmitry V. Shcheblyakov, I. B. Esmagambetov et al. · Frontiers in Immunology · 2022 · 38 citations · Full text

Pharmacy, Immunology, Infectious Diseases +17